|Jmol-3D images||Image 1|
|Molar mass||125.15 g mol−1|
|Density||1.734 g/cm3 (at −173.15 °C)|
|Melting point||305.11 °C|
|Acidity (pKa)||<0, 9.06|
| (what is: / ?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Taurine, or 2-aminoethanesulfonic acid, is an organic acid widely distributed in animal tissues. It is a major constituent of bile and can be found in the large intestine and accounts for approximately 0.1% of total human body weight. Taurine has many fundamental biological roles such as conjugation of bile acids, antioxidation, osmoregulation, membrane stabilization and modulation of calcium signaling. It is essential for cardiovascular function, and development and function of skeletal muscle, the retina and the central nervous system. Taurine is unusual among biological molecules in being a sulfonic acid, while the vast majority of biologically occurring acids contain the more weakly acidic carboxyl group. While taurine is sometimes called an amino acid, and indeed is an acid containing an amino group, it is not an amino acid in the usual biochemical meaning of the term, which refers to compounds containing both an amino and a carboxyl group.
Discovery and etymology
Taurine is named after the Latin taurus (a cognate of the Greek ταύρος) which means bull or ox, as it was first isolated from ox bile in 1827 by German scientists Friedrich Tiedemann and Leopold Gmelin.
Taurine is a derivative of cysteine, an amino acid which contains a thiol group. Taurine is one of the few known naturally occurring sulfonic acids. In the strict sense, it is not an amino acid, as it lacks a carboxyl group, but it is often called one, even in scientific literature. It does contain a sulfonate group and may be called an amino sulfonic acid. Small polypeptides have been identified which contain taurine, but to date no aminoacyl tRNA synthetase has been identified as specifically recognizing taurine and capable of incorporating it into a tRNA.
Taurine occurs naturally in food, especially in seafood and meat. The mean daily intake from omnivore diets was determined to be around 58 mg (range from 9 to 372 mg) and to be low or negligible from a strict vegan diet. In another study, taurine intake was estimated to be generally less than 200 mg/day, even in individuals eating a high-meat diet. According to another study, taurine consumption was estimated to vary between 40 and 400 mg/day. 
Taurine is a major constituent of bile and can be found in the large intestine and in the tissues of many animals, including humans. Mammalian taurine synthesis occurs in the pancreas via the cysteine sulfinic acid pathway. In this pathway, the thiol group of cysteine is first oxidized to cysteine sulfinic acid by the enzyme cysteine dioxygenase. Cysteine sulfinic acid, in turn, is decarboxylated by sulfinoalanine decarboxylase to form hypotaurine. It is unclear whether hypotaurine is then spontaneously or enzymatically oxidized to yield taurine.
A study of mice hereditarily unable to transport taurine suggests that it is needed for proper maintenance and functioning of skeletal muscles. In addition, it has been shown to be effective in removing fatty liver deposits in rats, preventing liver disease, and reducing cirrhosis in tested animals. There is also evidence that taurine is beneficial for adult human blood pressure and possibly, the alleviation of other cardiovascular ailments (in humans suffering essential hypertension, taurine supplementation resulted in measurable decreases in blood pressure).
A 2003 study by the European Food Safety Authority found no adverse effects for up to 1,000 mg of taurine per kilogram of body weight per day.
A review published in 2008 found no documented reports of negative or positive health effects associated with the amount of taurine used in energy drinks, concluding that "The amounts of guarana, taurine, and ginseng found in popular energy drinks are far below the amounts expected to deliver either therapeutic benefits or adverse events".
Chemical synthesis and commercial production
Synthetic taurine is obtained from isethionic acid (2-hydroxyethanesulfonic acid), which in turn is obtained from the reaction of ethylene oxide with aqueous sodium bisulfite. Another approach is the reaction of aziridine with sulfurous acid. This leads directly to taurine.
In 1993, approximately 5,000–6,000 tons of taurine were produced for commercial purposes; 50% for pet food manufacture, 50% in pharmaceutical applications. As of 2010, China alone has more than 40 manufacturers of taurine. Most of these enterprises employ the ethanolamine method to produce a total annual production of about 3,000 tons.
Taurine is essential for cardiovascular function, and development and function of skeletal muscle, the retina and the central nervous system.
Taurine is conjugated via its amino terminal group with chenodeoxycholic acid and cholic acid to form the bile salts sodium taurochenodeoxycholate and sodium taurocholate. The low pKa of taurine's sulfonic acid group ensures this moiety is negatively charged in the pH ranges normally found in the intestinal tract and, thus, improves the surfactant properties of the cholic acid conjugate.
Taurine crosses the blood–brain barrier and has been implicated in a wide array of physiological phenomena including inhibitory neurotransmission, long-term potentiation in the striatum/hippocampus, membrane stabilization, feedback inhibition of neutrophil/macrophage respiratory burst, adipose tissue regulation and possible prevention of obesity, calcium homeostasis, recovery from osmotic shock, protection against glutamate excitotoxicity and prevention of epileptic seizures.
It also acts as an antioxidant and protects against toxicity of various substances (such as lead and cadmium). Additionally, supplementation with taurine has been shown to prevent oxidative stress induced by exercise.
In a 2008 study, taurine has been shown to reduce the secretion of apolipoprotein B100 and lipids in HepG2 cells. High concentrations of serum lipids and apolipoprotein B100 (essential structural component of VLDL and LDL) are major risk factors of atherosclerosis and coronary heart disease. Hence, taurine supplementation is possibly beneficial for the prevention of these diseases.
In a 2003 study, Zhang et al. have demonstrated the hypocholesterolemic (blood cholesterol-lowering) effect of dietary taurine in young overweight adults. Furthermore, they reported body weight also decreased significantly in the taurine supplemented group. These findings are consistent with animal studies.
In cells, taurine keeps potassium and magnesium inside the cell, while keeping excessive sodium out. In this sense, it works like a diuretic. Because it aids the movement of potassium, sodium, and calcium in and out of the cell, taurine has been used as a dietary supplement for epileptics, as well as for people who have uncontrollable facial twitches.
Taurine is necessary for normal skeletal muscle functioning. This was shown by a 2004 study using mice with a genetic taurine deficiency. They had a nearly complete depletion of skeletal and cardiac muscle taurine levels. These mice had a reduction of more than 80% of exercise capacity compared to control mice. The authors expressed themselves as "surprised" their cardiac function showed as largely normal (given various other studies about effects of taurine on the heart).
Studies have shown taurine can influence (and possibly reverse) defects in nerve blood flow, motor nerve conduction velocity, and nerve sensory thresholds in experimental diabetic neuropathic rats.
In another study on diabetic rats, taurine significantly decreased weight and decreased blood sugar in these animal models. Likewise, a 2008 study demonstrated taurine administration to diabetic rabbits resulted in 30% decrease in serum glucose levels. According to the single study on human subjects, daily administration of 1.5g taurine had no significant effect on insulin secretion or insulin sensitivity. There is evidence that taurine may exert a beneficial effect in preventing diabetes-associated microangiopathy and tubulointerstitial injury in diabetic nephropathy.
Taurine acts as a glycation inhibitor. Studies have shown taurine-treated diabetic rats had a decrease in the formation of advanced glycation end products (AGEs) and AGEs content. The United States Department of Agriculture has found a link between cataract development and lower levels of vitamin B6, folate, and taurine in the diets of the elderly.
Taurine is involved in a number of crucial physiological processes. However, the role of taurine in these processes is not clearly understood and the influence of high taurine doses on these processes is uncertain. A substantial increase in the plasma concentration of growth hormone was reported in some epileptic patients during taurine tolerance testing (oral dose of 50 mg per kg body mass per day), suggesting a potential to stimulate the hypothalamus and to modify neuroendocrine function. A 1966 study found an indication that taurine (2 g/day) has some function in the maintenance and possibly in the induction of psoriasis. Three later studies failed to support that finding. It may also be necessary to take into consideration that absorption of taurine from beverages may be more rapid than from foods.
In animal nutrition
Taurine is an essential dietary requirement for feline health, since cats cannot synthesize the compound. The absence of taurine causes a cat's retina to slowly degenerate, causing eye problems and (eventually) irreversible blindness – a condition known as central retinal degeneration (CRD), as well as hair loss and tooth decay. Decreased plasma taurine concentration has been demonstrated to be associated with feline dilated cardiomyopathy. Unlike CRD, the condition is reversible with supplementation. Taurine is now a requirement of the Association of American Feed Control Officials (AAFCO) and any dry or wet food product labeled approved by the AAFCO should have a minimum of 0.1% taurine in dry food and 0.2% in wet food.
Research suggests taurine is essential to the normal development of passerine birds. Many passerines seek out taurine-rich spiders to feed their young, particularly just after hatching. Researchers compared the behaviors and development of birds fed a taurine-supplemented diet to a control diet and found the juveniles fed taurine-rich diets as neonates were much larger risk takers and more adept at spatial learning tasks.
Lately[when?], cosmetic compositions containing taurine have been introduced, possibly due to its antifibrotic properties. It has been shown to prevent the damaging effects of TGFB1 to hair follicles. It also helps to maintain skin hydration.
Prematurely born infants are believed to lack the enzymes needed to convert cystathionine to cysteine, and may, therefore, become deficient in taurine. Taurine is present in breast milk, and has been added to many infant formulas, as a measure of prudence, since the early 1980s. However, this practice has never been rigorously studied, and as such it has yet to be proven to be necessary, or even beneficial.
Taurine is also used in some contact lens solutions.
- Huxtable RJ (1992). "Physiological actions of taurine". Physiol Rev 72 (1): 101–163. PMID 1731369.
- F. Tiedemann, L. Gmelin (1827). "Einige neue Bestandtheile der Galle des Ochsen". Annalen der Physik 85 (2): 326–37. Bibcode:1827AnP....85..326T. doi:10.1002/andp.18270850214.
- Carey, FA (2006). Organic Chemistry (6th ed.). New York: McGraw Hill. p. 1149. ISBN 0-07-282837-4. "Amino acids are carboxylic acids that contain an amine function."
- Stapleton, PP; L O'Flaherty, HP Redmond, and DJ Bouchier-Hayes (1998). "Host defense--a role for the amino acid taurine?". Journal of Parenteral and Enteral Nutrition 22 (1): 42–8. doi:10.1177/014860719802200142. PMID 9437654.
- Weiss, SJ; Klein R, Slivka A, Wei M (1982). "Chlorination of Taurine by Human Neutrophils". Journal of Clinical Investigation 70 (3): 598–607. doi:10.1172/JCI110652. PMC 370261. PMID 6286728.
- Kirk, K; Kirk, J (1993). "Volume-regulatory taurine release from a human heart cancer cell line". FEBS Letters 336 (1): 153–8. doi:10.1016/0014-5793(93)81630-I. PMID 8262200.
- Lahdesmaki, P (1987). "Biosynthesis of taurine peptides in brain cytoplasmic fraction in vitro". Int J Neuroscience 37 (1–2): 79–84. doi:10.3109/00207458708991804.
- "Opinion on Caffeine, Taurine and D-Glucurono — g -Lactone as constituents of so-called "energy" drinks". Directorate-General Health and Consumers, European Commission, European Union. 1999-01-21.
- Bouckenooghe T, Remacle C, Reusens B (2006). "Is taurine a functional nutrient?". Current Opinion in Clinical Nutrition and Metabolic Care 9 (6): 728–33. doi:10.1097/01.mco.0000247469.26414.55. PMID 17053427.
- Brosnan J, Brosnan M (2006). "The sulfur-containing amino acids: an overview". J Nutr 136 (6 Suppl): 1636S–40S. PMID 16702333.
- U. Warskulat, U. Flogel, C. Jacoby, H.-G. Hartwig, M. Thewissen, M. W. Merx, A. Molojavyi, B. Heller-Stilb, J. Schrader and D. Haussinger (2004). "Taurine transporter knockout depletes muscle taurine levels and results in severe skeletal muscle impairment but leaves cardiac function uncompromised". The FASEB Journal 18 (3): 03–0496fje. doi:10.1096/fj.03-0496fje. PMID 14734644.
- Kerai, MDJ; Catherine J. Waterfield, S. H. Kenyon, D. S. Asker, J. A. Timbrell (1998). "Taurine: Protective properties against ethanol-induced hepatic steatosis and lipid peroxidation during chronic ethanol consumption in rats". Amino Acids 15 (1–2). doi:10.1007/BF01345280. PMID 9871487.
- McCall, B (2005-12-28). "The ultimate hangover cure?". bbc.co.uk. Retrieved 2008-09-01.
- rockstar69.com Original Rockstar Ingredients
- Chang, PL (2008-05-03). "Nos Energy Drink – Review". energyfanatics.com. Retrieved 2010-05-21.
- EFSA adopts opinion on two ingredients commonly used in some energy drinks efsa.europa.eu/
- Clauson, KA; Shields, KM; McQueen, CE; Persad, N (2008). "Safety issues associated with commercially available energy drinks". Journal of the American Pharmacists Association : JAPhA 48 (3): e55–63; quiz e64–7. doi:10.1331/JAPhA.2008.07055. PMID 18595815.
- Kosswig K, ed. (2000). "Sulfonic Acids, Aliphatic". Ullmann's Encyclopedia of Industrial Chemistry. Wiley-VCH. doi:10.1002/14356007.a25_503.
- Tully PS, ed. (2000). "Sulfonic Acids". Kirk-Othmer Encyclopedia of Chemical Technology. John Wiley & Sons, Inc. doi:10.1002/0471238961.1921120620211212.a01.
- Amanda Xia (2010-01-03). "China Taurine Market Is Expected To Recover". Press release and article directory: technology. megapremium.info. Retrieved 2010-05-24.
- Huxtable, RJ (1992). "Physiological actions of taurine". Physiol Rev 72 (1): 101–63. PMID 1731369.
- Irving CS, Hammer BE, Danyluk SS, Klein PD (1980). "13C Nuclear Magnetic Resonance Study of the Complexation of Calcium by Taurine". Journal of Inorganic Biochemistry 13 (2): 137–50. doi:10.1016/S0162-0134(00)80117-8. PMID 7431022.
- Urquhart, N; Perry, TL; Hansen, S; Kennedy, J (1974). "Passage of taurine into adult mammalian brain". Journal of Neurochemistry 22 (5): 871–2. doi:10.1111/j.1471-4159.1974.tb04309.x. PMID 4407108.
- Tsuji, A; Tamai, I (1996). "Sodium- and chloride-dependent transport of taurine at the blood–brain barrier". Advances in Experimental Medicine and Biology 403: 385–91. PMID 8915375.
- Salimäki, J; Scriba, G; Piepponen, TP; Rautolahti, N; Ahtee, L (2003). "The effects of systemically administered taurine and N-pivaloyltaurine on striatal extracellular dopamine and taurine in freely moving rats". Naunyn-Schmiedeberg's Archives of Pharmacology 368 (2): 134–41. doi:10.1007/s00210-003-0776-6.
- Olive, MF (2002). "Interactions between taurine and ethanol in the central nervous system". Amino Acids 23 (4): 345–57. doi:10.1007/s00726-002-0203-1. PMID 12436202.
- Dominy, J Jr; Thinschmidt, JS; Peris, J; Dawson, R Jr; Papke, RL (2004). "Taurine-induced long-lasting potentiation in the rat hippocampus shows a partial dissociation from total hippocampal taurine content and independence from activation of known taurine transporters". Journal of Neurochemistry 89 (5): 1195–205. doi:10.1111/j.1471-4159.2004.02410.x. PMID 15147512.
- Birdsall, TC (1998). "Therapeutic applications of taurine". Alternative Medicine Review 3 (2): 128–36. PMID 9577248.
- Ide T, Kushiro M, Takahashi Y, Shinohara K, Cha S. "mRNA expression of enzymes involved in taurine biosynthesis in rat adipose tissues. Metabolism: Clinical and Experimental 2002 Sep;51(9):1191-7.
- Tsuboyama-Kasaoka, N; Shozawa, C; Sano, K; Kamei, Y; Kasaoka, S; Hosokawa, Y; Ezaki, O (2006). "Taurine (2-aminoethanesulfonic acid) deficiency creates a vicious circle promoting obesity". Endocrinology 147 (7): 3276–84. doi:10.1210/en.2005-1007. PMID 16627576.
- Foos, TM; Wu, JY (2002). "The role of taurine in the central nervous system and the modulation of intracellular calcium homeostasis". Neurochemical Research 27 (1–2): 21–6. doi:10.1023/A:1014890219513. PMID 11926272.
- Stummer W, Betz AL, Shakui P, Keep RF (1995). "Blood–brain barrier taurine transport during osmotic stress and in focal cerebral ischemia". Journal of Cerebral Blood Flow and Metabolism 15 (5): 852–9. doi:10.1038/jcbfm.1995.106. PMID 7673378.
- Leon R, Wu H, Jin Y, Wei J, Buddhala C, Prentice H, Wu JY (2008). "Protective function of taurine in glutamate-induced apoptosis in cultured neurons". Journal of Neuroscience Research.
- El Idrissi A, Messing J, Scalia J, Trenkner E (2003). "Prevention of epileptic seizures by taurine". Advances in Experimental Medicine and Biology 526: 515–25.
- Green, TR; Fellman, JH; Eicher, AL; Pratt, KL (1991). "Antioxidant role and subcellular location of hypotaurine and taurine in human neutrophils". Biochimica et Biophysica Acta 1073 (1): 91–7. doi:10.1016/0304-4165(91)90187-L. PMID 1846756.
- Gürer, H; Ozgünes, H; Saygin, E; Ercal, N (2001). "Antioxidant effect of taurine against lead-induced oxidative stress". Archives of Environmental Contamination and Toxicology 41 (4): 397–402. doi:10.1007/s002440010265. PMID 11598776.
- Das, J; Ghosh, J; Manna, P; Sil, PC (2008). "Taurine provides antioxidant defense against NaF-induced cytotoxicity in murine hepatocytes". Pathophysiology 15 (3): 181–90. doi:10.1016/j.pathophys.2008.06.002. PMID 18676123.
- Sinha, M; Manna, P; Sil, PC (2008). "Taurine protects the antioxidant defense system in the erythrocytes of cadmium treated mice". BMB Reports 41 (9): 657–63. doi:10.5483/BMBRep.2008.41.9.657. PMID 18823590.
- Zhang M, Izumi I, Kagamimori S, Sokejima S, Yamagami T, Liu Z, Qi B (2004). "Role of taurine supplementation to prevent exercise-induced oxidative stress in healthy young men". Amino Acids 26 (2): 203–7. doi:10.1007/s00726-003-0002-3. PMID 15042451.
- Yanagita, T; Han, SY; Hu, Y; Nagao, K; Kitajima, H; Murakami, S (2008). "Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells". Lipids in Health and Disease 7: 38.
- Zhang, M; Bi, LF; Fang, JH; Su, XL; Da, GL; Kuwamori, T; Kagamimori, S (2004). "Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects". Amino Acids 26 (3): 267–71. doi:10.1007/s00726-003-0059-z. PMID 15221507.
- Choi, MJ; Kim, JH; Chang, KJ (2006). "The effect of dietary taurine supplementation on plasma and liver lipid concentrations and free amino acid concentrations in rats fed a high-cholesterol diet". Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology 583: 235–42. doi:10.1007/978-0-387-33504-9_25. ISBN 978-0-387-32356-5. PMID 17153607.
- Congestive Heart Failure, Healthnotes, Inc, PeaceHealth, January 19, 2007
- Laidlaw S, Shultz T, Cecchino J, Kopple J (1988). "Plasma and urine taurine levels in vegans". American Journal of Clinical Nutrition 47 (4): 660–3. PMID 3354491.
- Kirk J and Kirk K. Inhibition of volume-activated I- and taurine efflux from HeLa cells by P-glycoprotein blockers correlates with calmodulin inhibition. J. Biol. Chem., Nov 1994;269:29389–29394.
- Kong WX, Chen SW, Li YL, et al. (2006). "Effects of taurine on rat behaviors in three anxiety models". Pharmacol. Biochem. Behav 83 (2): 271–6. doi:10.1016/j.pbb.2006.02.007. PMID 16540157.
- Zhang, CG; Kim, SJ (2007). "Taurine induces anti-anxiety by activating strychnine-sensitive glycine receptor in vivo". Annals of Nutrition & Metabolism 51 (4): 379–86. doi:10.1159/000107687.
- Chen, SW; Kong, WX; Zhang, YJ; Li, YL; Mi, XJ; Mu, XS (2004). "Possible anxiolytic effects of taurine in the mouse elevated plus-maze". Life Sciences 75 (12): 1503–11. doi:10.1016/j.lfs.2004.03.010. PMID 15240184.
- Li F, Abatan OI, Kim H, Burnett D, Larkin D, Obrosova IG, Stevens MJ (2006). "Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats". Neurobiology of Disease 22 (3): 669–76. doi:10.1016/j.nbd.2006.01.012. PMID 16624563.
- Pop-Busui R, Sullivan KA, Van Huysen C, Bayer L, Cao X, Towns R, Stevens MJ (2001). "Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, and functional deficits". Exp Neurol 168 (2): 259–72. doi:10.1006/exnr.2000.7591. PMID 11259114.
- Yutaka Nakaya, Asako Minami, Nagakatsu Harada, Sadaichi Sakamoto, Yasuharu Niwa and Masaharu Ohnaka (2000). "Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes". American Journal of Clinical Nutrition 71 (1): 54–8. PMID 10617946.
- Winiarska K, Szymanski K, Gorniak P, Dudziak M, Bryla J (2008). "Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits". Biochimie.
- C. Brøns, C. Spohr, H. Storgaard, J. Dyerberg, A. Vaag. "Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus. European Journal of Clinical Nutrition (2004) 58, 1239–1247.
- Wu QD, Wang JH, Fennessy F, Redmond HP, Bouchier-Hayes D (1999). "Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis". The American journal of physiology 277 (6 Pt 1): C1229–38. PMID 10600775.
- Verzola, D; Bertolotto, MB; Villaggio, B; Ottonello, L; Dallegri, F; Frumento, G; Berruti, V; Gandolfo, MT et al. (2002). "Taurine prevents apoptosis induced by high ambient glucose in human tubule renal cells". Journal of investigative medicine: the official publication of the American Federation for Clinical Research 50 (6): 443–51.
- Effects of taurine on advanced glycosylation end products and expression of TGF-β in renal cortex of, TsingHua, 2005, http://www.shvoong.com/medicine-and-health/1599878-effects-taurine-advanced-glycosylation-end/
- Huang JS, Chuang LY, Guh JY, Yang YL, Hsu MS (2008). "Effect of taurine on advanced glycation end products-induced hypertrophy in renal tubular epithelial cells". Toxicology and Applied Pharmacology 233 (2): 220–6. doi:10.1016/j.taap.2008.09.002. PMID 18834896.
- "ARS: 50 Years of Research for the Growing World". Ars.usda.gov. Retrieved 2012-10-27.
- "Evaluation Of Taurine As An Osmotic Agent For Peritoneal Dialysis Solution". Pdiconnect.com. Retrieved 2012-10-27.
- Zackheim, Herschel S; Farber, Eugene M (1968). "Taurine and Psoriasis". The Journal of Investigative Dermatology 50 (3): 227–230. doi:10.1038/jid.1968.32. Retrieved 2013-11-23.
- Zackheim, Herschel S. (1982). "Taurine and Diet in Psoriasis". Archives of Dermatology 118 (12): 961. doi:10.1001/archderm.1982.01650240005005. Retrieved 2013-11-23.
- Zackheim, Herschel S.; Farber, Eugene M. (1969). "Low-Protein Diet and Psoriasis A Hospital Study". Archives of Dermatology 99 (5): 580–586. doi:10.1001/archderm.1969.01610230072012. Retrieved 2013-11-23.
- "Taurine And Its Importance In Cat Foods". Iams Cat Nutrition Library. 2004. Archived from the original on 2006-10-19. Retrieved 2006-08-22.
- "Nutrient Requirements of Cats". Nutrient Requirements of Cats, Revised Edition, 1986. 1986. Retrieved 2006-09-10.
- Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy
- Arnold, KE; Ramsay, S.L.; Donaldson, C.; Adam, A (2007). "Parental prey selection affects risk-taking behaviour and spatial learning in avian offspring". Proceedings of the Royal Society B 274 (1625): 2563–9. doi:10.1098/rspb.2007.0687. PMC 2275882. PMID 17698490.
- Collin, C; Gautier, B; Gaillard, O; Hallegot, P; Chabane, S; Bastien, P; Peyron, M; Bouleau, M et al. (2006). "Protective effects of taurine on human hair follicle grown in vitro". International Journal of Cosmetic Science 28 (4): 289–98. doi:10.1111/j.1467-2494.2006.00334.x. ISSN 0142-5463. PMID 18489269. "We showed that taurine [...] prevented TGF-β1-induced deleterious effects on hair follicle."
- Janeke G, Siefken W, Carstensen S, Springmann G, Bleck O, Steinhart H, Höger P, Wittern KP, Wenck H, Stäb F, Sauermann G, Schreiner V, Doering T (2003). "Role of taurine accumulation in keratinocyte hydration". The Journal of Investigative Dermatology 121 (2): 354–61. doi:10.1046/j.1523-1747.2003.12366.x. PMID 12880428.
- Heird W.C. "Taurine in neonatal nutrition—revisited," Archives of Disease in Childhood: Fetal Neonatal. 2004 November; 89(6): F473-F474. doi:10.1136/adc.2004.055095
- James, TJ; Hansen D; Nolfi, J (2004-04-01). "Ocular Health and Next Generation Solutions". Optometric Management. Retrieved 2008-01-10.